Compare MSS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | PPBT |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.4M |
| IPO Year | 2023 | 2014 |
| Metric | MSS | PPBT |
|---|---|---|
| Price | $0.95 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.50 | $30.00 |
| AVG Volume (30 Days) | ★ 229.5K | 36.3K |
| Earning Date | 03-17-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,217,480.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.01 | N/A |
| 52 Week Low | $0.11 | $0.41 |
| 52 Week High | $3.96 | $5.18 |
| Indicator | MSS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 32.66 |
| Support Level | $0.83 | $0.57 |
| Resistance Level | $1.03 | $4.39 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 7.05 | 18.70 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.